Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors

• Published in: Microorganisms (Basel) Vol. 10; no. 7; p. 1299
• Main Authors: Alexandrova, Liudmila A, Khandazhinskaya, Anastasia L, Matyugina, Elena S, Makarov, Dmitriy A, Kochetkov, Sergey N
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 27.06.2022; MDPI
• Subjects: Antibacterial agents; Antibiotics; Biosynthesis; Carbohydrates; Cell culture; Chemical activity; Chemical properties; Cytotoxicity; Drug resistance; Drug resistance in microorganisms; Drug therapy; Enzymes; Health aspects; Hydrocarbons; Inhibitors; Multidrug resistance; mycobacteria; Mycobacterium tuberculosis; Nucleoside analogs; nucleoside analogues; Nucleosides; Pharmaceutical research; Pharmacology; Pyrimidines; Review; thymidine monophosphate kinase; Tuberculosis; Vaccination; Russia
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms10071299

Tuberculosis (TB) is the oldest human infection disease. Mortality from TB significantly decreased in the 20th century, because of vaccination and the widespread use of antibiotics. However, about a third of the world’s population is currently infected with Mycobacterium tuberculosis (Mtb) and the death rate from TB is about 1.4–2 million people per year. In the second half of the 20th century, new extensively multidrug-resistant strains of Mtb were identified, which are steadily increasing among TB patients. Therefore, there is an urgent need to develop new anti-TB drugs, which remains one of the priorities of pharmacology and medicinal chemistry. The antimycobacterial activity of nucleoside derivatives and analogues was revealed not so long ago, and a lot of studies on their antibacterial properties have been published. Despite the fact that there are no clinically used drugs based on nucleoside analogues, some progress has been made in this area. This review summarizes current research in the field of the design and study of inhibitors of mycobacteria, primarily Mtb.